Daniel S Park, PA-C | |
200 Brule St Bldg 871, Fort Knox, KY 40121-6100 | |
(502) 624-9333 | |
Not Available |
Full Name | Daniel S Park |
---|---|
Gender | Male |
Speciality | Military Health Care Provider |
Location | 200 Brule St Bldg 871, Fort Knox, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225741952 | NPI | - | NPPES |
1204605 | Other | NCCPA IDENTIFICATION NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
171000000X | Military Health Care Provider | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Daniel S Park, PA-C 1166 Ne Laurel Ct, Issaquah, WA 98029-7676 Ph: (206) 778-9459 | Daniel S Park, PA-C 200 Brule St Bldg 871, Fort Knox, KY 40121-6100 Ph: (502) 624-9333 |
News Archive
Dr. Julie Gerberding, director, Centers for Disease Control and Prevention ,speaking at the National Immunization Conference Washington, DC, says the rubella virus, a major cause of serious birth defects such as deafness and blindness, also known as congenital rubella syndrome (CRS) is no longer considered to be a major public health threat in the United States.
PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.
Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.
Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid-, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.
› Verified 1 days ago